Anzeige
Mehr »
Login
Donnerstag, 22.04.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
Massive, hochgradige Goldadern! Das ist die Clarity-Wette!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DLU2 ISIN: SE0009414576 Ticker-Symbol: OND 
Stuttgart
21.04.21
08:30 Uhr
12,530 Euro
+0,120
+0,97 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ONCOPEPTIDES AB Chart 1 Jahr
5-Tage-Chart
ONCOPEPTIDES AB 5-Tage-Chart
RealtimeGeldBriefZeit
12,42012,93021.04.

Aktuelle News zur ONCOPEPTIDES Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrOncopeptides submits application for conditional marketing authorization of melflufen in the EU145STOCKHOLM, April 16, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological...
► Artikel lesen
ONCOPEPTIDES Aktie jetzt für 0€ handeln
FrONCOPEPTIDES AB: Oncopeptides submits application for conditional marketing authorization of melflufen in the EU1
31.03.Number of shares and votes in Oncopeptides158STOCKHOLM, March 31, 2021 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed due to the exercise of warrants...
► Artikel lesen
31.03.ONCOPEPTIDES AB: Number of shares and votes in Oncopeptides1
22.03.Oncopeptides announces that PEPAXTO is included in new Multiple Myeloma guidelines of National Comprehensive Cancer Network164STOCKHOLM, March 22, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological...
► Artikel lesen
22.03.Oncopeptides' PEPAXTO added to U.S. cancer network-
22.03.ONCOPEPTIDES AB: Oncopeptides announces that PEPAXTO is included in new Multiple Myeloma guidelines of National Comprehensive Cancer Network1
15.03.Oncopeptides announces that the first patients in the United States are being treated with PEPAXTO189STOCKHOLM, March 15, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological...
► Artikel lesen
15.03.ONCOPEPTIDES AB: Oncopeptides announces that the first patients in the United States are being treated with PEPAXTO-
08.03.Oncopeptides strengthens leadership in Europe and opens an Early Access Program in multiple myeloma228STOCKHOLM, March 8, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological...
► Artikel lesen
27.02.FDA approves Oncopeptides' PEPAXTO ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma619STOCKHOLM, Feb. 26, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological...
► Artikel lesen
26.02.ONCOPEPTIDES AB: FDA approves Oncopeptides' PEPAXTO ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma7
18.02.Oncopeptides AB reports Q4 results1
18.02.Oncopeptides AB: Year-end Report 2020199STOCKHOLM, Feb. 18, 2021 /PRNewswire/ -- Summary Q4 Financial overview October 1 - December 31, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 513.0 M (loss:...
► Artikel lesen
21.12.20ONCOPEPTIDES AB: Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma1
21.12.20Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma262STOCKHOLM, Dec. 21, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the first patient has been dosed in the phase 3 LIGHTHOUSE study, evaluating...
► Artikel lesen
15.12.20Oncopeptides strengthens its organization by appointing Linda Holmström as Director of Investor Relations236STOCKHOLM, Dec. 15, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological...
► Artikel lesen
15.12.20ONCOPEPTIDES AB: Oncopeptides strengthens its organization by appointing Linda Holmström as Director of Investor Relations2
10.12.20Full data set of Oncopeptides phase 2 HORIZON study in multiple myeloma published in the Journal of Clinical Oncology353STOCKHOLM, Dec. 10, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat...
► Artikel lesen
09.12.20ONCOPEPTIDES AB: Full data set of Oncopeptides phase 2 HORIZON study in multiple myeloma published in the Journal of Clinical Oncology2
Seite:  Weiter >>
62 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1